Apellis Pharmaceuticals, Inc.
APLS
$23.19
-$0.30-1.28%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 178.49M | 166.80M | 212.53M | 196.83M | 199.69M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 178.49M | 166.80M | 212.53M | 196.83M | 199.69M |
| Cost of Revenue | 80.64M | 120.78M | 117.21M | 122.13M | 101.05M |
| Gross Profit | 97.85M | 46.02M | 95.32M | 74.70M | 98.64M |
| SG&A Expenses | 131.14M | 129.35M | 121.48M | 121.98M | 128.08M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 211.78M | 250.13M | 238.69M | 244.11M | 229.13M |
| Operating Income | -33.29M | -83.33M | -26.16M | -47.28M | -29.44M |
| Income Before Tax | -41.69M | -91.88M | -36.07M | -56.85M | -37.54M |
| Income Tax Expenses | 466.00K | 341.00K | 286.00K | 592.00K | 114.00K |
| Earnings from Continuing Operations | -42.15M | -92.23M | -36.35M | -57.45M | -37.66M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -42.15M | -92.23M | -36.35M | -57.45M | -37.66M |
| EBIT | -33.29M | -83.33M | -26.16M | -47.28M | -29.44M |
| EBITDA | -32.84M | -82.88M | -25.72M | -46.82M | -28.99M |
| EPS Basic | -0.33 | -0.74 | -0.29 | -0.46 | -0.30 |
| Normalized Basic EPS | -0.21 | -0.46 | -0.18 | -0.29 | -0.18 |
| EPS Diluted | -0.33 | -0.74 | -0.29 | -0.46 | -0.30 |
| Normalized Diluted EPS | -0.21 | -0.46 | -0.18 | -0.29 | -0.18 |
| Average Basic Shares Outstanding | 126.02M | 125.45M | 124.52M | 124.23M | 123.90M |
| Average Diluted Shares Outstanding | 126.02M | 125.45M | 124.52M | 124.23M | 123.90M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |